NIH awards grant for influenza identification process

Biotechnology company InDevR has been awarded a $3 million Phase II Small Business Innovation Research grant from the National Institutes of Health over the next three years to study an influenza identification process known as FluChip technology.   

The grant is titled “Simultaneous Screening for A/H3N2, A/H1N1, A/H5N1 and B Influenza Viruses” and will fund the development of an influenza screening integrated sample-to-result molecular diagnostic platform.

"We are delighted to receive continued support from the NIH to advance our FluChip technology for accurate, rapid and cost-effective identification of influenza viruses," Kathy L. Rowlen, InDevR's CEO and chief science officer, said.

InDevR received the grant after the completion of a successful two year Phase I award that was worth $600,000. That grant was used to refine a low-density microarray assay for influenza virus identification.

Efforts for Phase II will focus on combining the FluChip low-density microarray with ampliPHOX, a colorimetric detection method. Then the entire assay will be integrated into a cost-effective, cartridge-based instrument platform targeted for eventual clinical diagnosis.

The foundational intellectual property that is associated with the FluChip and ampliPHOX technologies has been licensed from the University of Colorado - Boulder.

"The combination of InDevR's FluChip and ampliPHOX technologies represents a promising and innovative approach and that could have high impact on influenza diagnostics,” David Allen, an associate vice president at the University of Colorado Technology Transfer Office, said.

Organizations in this story

National Institutes of Health 9000 Rockville Pike Bethesda, MD 20892

Get notified the next time we write about National Institutes of Health!